[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"caspr2-antibody\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:caspr2-antibody":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100603176","medium-term-effects-of-treatments-in-autoimmune-encephalitis-100603176",false,"NCT07133113","Medium-term Effects of Treatments in Autoimmune Encephalitis","Medium-term Effects of Treatments in Autoimmune Encephalitis (META): a Real-life, Observational Prospective Study","META","Inclusion Criteria:\n\n* Adult or child patient with encephalitis defined as anti-GAD, NMDAR, LGI1, CASPR2, IgLON5 or GFAP\n* Untreated or with a decision to treat within the previous 30 days.\n\nExclusion Criteria:\n\n\\- Refusal by the referring doctor to participate or refusal by the patient mentioned in the objection to the use of his\u002Fher clinical data.","ALL",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence. Commonly used treatments are divided into so-called first-line (steroids, intravenous immunoglobulins, plasma exchanges) and second-line (rituximab, cyclophosphamide, tocilizumab, others), and may be used in association or sequentially. There is no standard practice, and initial treatment protocol may consist in first-line alone, first-line with rituximab, or first-line with dual immunosuppression (rituximab and cyclophosphamide). Absence of clear response to initial treatment in the first 4 to 6 weeks may indicate undertreatment and is generally followed by treatment escalation, mostly to dual immunosuppression. However, as the frequency of non-responders to initial treatment is unknown, it is still unclear whether dual immunosuppression should be offered to all patients from inception.",[24,25,26,27,28,29],"NMDAR Autoimmune Encephalitis","LGI1 Antibody Associated Encephalitis","CASPR2-Antibody","IgLON5","GAD65","GFAP",[31,32],"Paraneoplastic neurological disorder","autoimmune encephalitis","RECRUITING","2025-08-13",{"date":36,"type":37},"2025-08-20","ACTUAL",{"date":39,"type":37},"2024-09-01",{"date":41,"type":20},"2027-03-01",{"name":43,"class":44},"Hospices Civils de Lyon","OTHER"]